SNAP-8
Acetyl Octapeptide-3 / Extended Argireline
Extended Argireline analogue with two additional amino acids for potentially greater SNARE inhibition at lower concentration. Often combined with Argireline for additive expression line reduction.
Mechanism of action
Same SNARE complex inhibition mechanism as Argireline but with an 8 amino acid chain. Theoretically greater efficacy at lower concentrations due to improved receptor affinity. Often combined with Argireline for additive effect through slightly different binding.
Effects in the body
SNAP-8 is Argirelines more refined sibling — same mechanism longer chain potentially higher efficacy at lower concentration. Often used together with Argireline for additive expression line reduction through complementary binding profiles.
Pros & cons (from the literature)
- Potentially more effective than Argireline at lower dose
- Same well understood SNARE mechanism
- Good tolerability profile
- Additive when combined with Argireline
- Less independent clinical evidence than Argireline
- Fewer human studies published
- More expensive than Argireline
- Mechanism only marginally different from Argireline
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
Manufacturer clinical data from Lipotec. Some independent human RCT evidence. Less replicated than Argireline but mechanistically credible.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.